Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

Gynecologic Oncology

Volumn 88, Issue 3, 2003, Pages 266-269

  D'Agostino, Giuseppe ^a,b   Amant, Frederic ^a   Berteloot, Patrick ^a   Scambia, Giovanni ^b   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Gemcitabine; Phase II; Recurrent ovarian cancer; Single agent

Indexed keywords

ERYTHROPOIETIN; GEMCITABINE; PACLITAXEL; PLATINUM;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037339485     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00011-8     Document Type: Article

References (24)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2000. CA Cancer J Clin. 52:2002;23-47.
2. McGuire W.P., Ozols R.F. Chemotherapy of advanced ovarian cancer. Semin Oncol. 25:1998;340-348.
3. Colombo N., Parma G., Bocciolone L., Sideri M., Franchi D., Maggioni A. Role of chemotherapy in relapsed ovarian cancer. Crit Rev Oncol Hematol. 32:1999;221-228.
4. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
5. Bookman M. Developmental chemotherapy in ovarian cancer incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182) . Semin Oncol. 29:(S1):2002;30-31.
6. Ozols R.F. Future directions in the treatment of ovarian cancer. Semin Oncol. 29:(S1):2002;32-42.
7. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine preclinical pharmacology and mechanisms of action . Semin Oncol. 23:(S10):1996;3-15.
8. Barton-Burke M. Gemcitabine a pharmacological and clinical overview . Cancer Nurs. 22:1999;176-183.
9. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer. J Natl Cancer Inst. 86:1994;1530-1533.
10. Shapiro J.D., Millward M.J., Rischin D., Michael N., Walker V., Francis P.a, et al. Activity of gemcitabine in patients with advanced ovarian cancer responses seen following platinum and paclitaxel . Gynecol Oncol. 63:1996;80-93.
11. Hansen S.W., Tuxen M.K., Sessa C. Gemcitabine in the treatment of ovarian cancer. Ann Oncol. 10:(S1):1999;51-53.
12. Markman M., Kennedy A., Webster K., Zanotti K., Kulp B., Peterson G., et al. Phase II trial of single-agent gemcitabine (GEM) in platinum (PLAT)/paclitaxel (PAC) refractory ovarian cancer (ROC). Proc Am Soc Clin Oncol. 20:2001;A813.
13. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:1982;49-55.
14. National Cancer Institute common toxicity criteria, Version 2.0 Revised March 23, 1998, http://ctep.info.nih.gov/CTC3/default.htm.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:2000;205-216.
16. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma a randomised phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol. 19:2001;3312-3322.
17. Coenen M., Berteloot P., Amant F., Vangramberen M., Vergote I. Gemcitabine in platin-paclitaxel resistant ovarian carcinoma. Proc Am Soc Clin Oncol. 19:2000;A1603.
18. Orlando M., Mandachain M. Gemcitabine in ovarian cancer. Semin Oncol. 28:(S10):2001;62-69.
19. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol. 29:(S.1):2002;9-10.
20. Cesano A., Lane S.R., Poulin R., Ross G., Fields S.Z. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol. 15:1999;1233-1238.
21. Cesano A., Lane S.R., Ross G.A., Fields S.Z. Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non small cell lung cancer patients. Int J Oncol. 7:2000;587-590.
22. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 22:(S11):1995;72-79.
23. Thigpen T. the role of gemcitabine-based doublets in the management of ovarian carcinoma. Semin Oncol. 29:(S1):2002;11-16.
24. D'Agostino G., Ferrandina G., Garganese G., Salerno M.G., Lorusso D., Farnetano M.G., et al. Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology. 62:2002;110-114.